Welcome to NextLevel Pharma’s PHARMACCESS LEADERS FORUM!
This is the must-attend event for all senior Market Access, HEOR, and Government Affairs directors from leading pharma and biotechnology companies. This 3 day event will give all attendees the insight and understanding of HTA, payer & market access stakeholders' decision-making processes and evaluation methods. It is designed so that the experiences over the 3 days are as value-adding and specifically relevant for every participant. Attendees will be able to understand and develop best practice approaches to vital and common patient access challenges, with the ultimate goal of encouraging innovation and improving access to novel and powerful medications which demonstrate “real value” to payers in their terms.
October 16-17 – 3rd Annual International Pharmaceutical Payers & HTA Summit (2 days)
This 2 day event will showcase highly-regarded thought-leaders from HTAs & Payer institutions and will allow them the chance to discuss and share their issues and directions on issues including: Policy development, Evidence interpretation, Decision-making and consolidation on Health-Related Quality of Life (HRQoL) metrics.
This insight will be invaluable to all industry representatives who are looking to bring their therapies to market under optimal reimbursement & access conditions.
The event will also cater for attendees from HTAs, Insurers (public & private) and Ministries of Health, who are looking to benchmark their evaluation processes against international peers and also understand the industry perspectives on submissions, value demonstration and product differentiation approaches.
October 18 – Choose your stream (from)
- Third Annual - AMNOG in Action – A follow on to our extremely thought-provoking sessions from last year and one that will bring with it another year of insights and enhanced clarity over the role and approach to take to one of Europe’s most influential markets. This will be an excellent opportunity to gain real AMNOG experiences and meet the experts who faced and overcame the first challenges that the AMNOG reform is presenting.
- Second Annual - Market Access for High Value Specialty & Biologic Medicines - This event will uniquely look at how to generate quality evidence and demonstrate value to global payers, HTAs and other key stakeholders for higher-cost drugs prescribed by specialists in various therapeutic areas with oncology a strong exmaple. Such drugs may include niche biologics, expensive small molecules, orphan drugs, personalized medicines or biosimilars.
- Market Access for Vaccines & Infectious Disease Medications – In a concise format this workshop will address the common evidence generation & value demonstration challenges for vaccine and infectious disease therapies. Challenges which will be addressed will include: Value-protection, Product assessment, Tendering, Procurement, Seasonality, Distribution and Patient access schemes to developing nations.
We look forward to hopefully meeting you in Berlin!